Cesca Therapeutics Inc. announced that its device subsidiary, ThermoGenesis, has signed a license agreement with IncoCell Tianjin, a wholly-owned subsidiary of Boyalife Group, for CAR-T related and other cellular processing CDMO services.    Under the agreement, ThermoGenesis has granted IncoCell an exclusive license to purchase and use, at a discounted purchase price, X-Series™ cellular processing research devices, consumables, and kits for use in the conduct of CDMO operations in certa...